Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Geert D'HaensMarla DubinskyTaku KobayashiPeter M IrvingStefanie HowaldtJuris PokrotnieksKathryn KruegerJanelle LaskowskiXingyuan LiTrevor LissoosJoe MilataNathan MorrisVipin AroraCatherine MilchWilliam SandbornBruce E Sandsnull nullPublished in: The New England journal of medicine (2023)
Mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis. Opportunistic infection or cancer occurred in a small number of patients treated with mirikizumab. (Funded by Eli Lilly; LUCENT-1 and LUCENT-2 ClinicalTrials.gov numbers, NCT03518086 and NCT03524092, respectively.).